Quantum BioPharma Advances Lucid-MS to Phase 2, Secures 7% Royalty Deal
QNTM•Quantum BioPharma's patented Lucid-MS, a first-in-class myelin-targeting MS therapy, is set to enter Phase 2 clinical trials following promising preclinical results. The company holds a 19.84% stake in Unbuzzd Wellness, earning a 7% royalty on OTC sales until $250 million in payments, then 3% thereafter.
1. Lucid-MS Phase 2 Preparations
Quantum BioPharma’s lead candidate, Lucid-MS, has demonstrated the ability to prevent and reverse myelin degradation in preclinical models and is now moving into Phase 2 clinical trials, marking a key inflection point for the company’s MS program.
2. Unbuzzd Wellness Royalty Agreement
Through its spin-off Unbuzzd Wellness Inc., Quantum retains a 19.84% equity stake and is entitled to a 7% royalty on OTC product sales until $250 million in total payments, after which royalties drop to 3% in perpetuity.
3. Biotech Portfolio and Rights Retention
Quantum maintains 100% ownership of pharmaceutical rights for Lucid-MS and related formulations, and continues to expand its pipeline targeting neurodegenerative, metabolic and alcohol misuse disorders alongside its MS asset.
